KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Biology / 2020 / Cilt: 44 - Sayı: SI-1

Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties

Erman Salih ISTİFLİ
Arzuhan Sihoglu TEPE
Cengiz SARİKURKCU
Bektas TEPE
Sayfa
242–264
Yayın Tarihi
2020-06-21
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Due to its interaction profile with target proteins and excellent pharmacokinetic properties, it has been concluded that carvone can be considered as an alternative agent in drug development studies against 2019-nCoV.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:As of June 2020, the coronavirus disease 19 (COVID-19) caused by the 2019 new type coronavirus (2019-nCoV) infected more than 7,000,000 people worldwide and caused the death of more than 400,000 people.
📊
Temel Bulgular & Veri:The aim of this study was to investigate the molecular interactions between monoterpenoids and spike protein of 2019-nCoV together with the cellular proteases [transmembrane serine protease 2 (TMPRSS2), cathepsin B (CatB), and cathepsin L (CatL)].
💡
Sonuç & Katkı:Due to its interaction profile with target proteins and excellent pharmacokinetic properties, it has been concluded that carvone can be considered as an alternative agent in drug development studies against 2019-nCoV.
🔬Tür:Araştırma Makalesi
📍Kapsam:2020 Verileri
⚙️Değişkenler:2019-nCoV · ACE2 · TMPRSS2

Abstract

As of June 2020, the coronavirus disease 19 (COVID-19) caused by the 2019 new type coronavirus (2019-nCoV) infected more than 7,000,000 people worldwide and caused the death of more than 400,000 people. The aim of this study was to investigate the molecular interactions between monoterpenoids and spike protein of 2019-nCoV together with the cellular proteases [transmembrane serine protease 2 (TMPRSS2), cathepsin B (CatB), and cathepsin L (CatL)]. As a result of the relative binding capacity index (RBCI) analysis, carvone was found to be the most effective molecule against all targets when binding energy and predicted (theoretical) IC50 data were evaluated together. It was found to exhibit drug-likeness property according to the Lipinski’s rule-of-five. Carvone has also been determined to be able to cross the blood-brain barrier (BBB) effectively, not a substrate for P-glycoprotein (P-gp), not to inhibit any of the cytochrome P molecules, and to have no toxic effects even on liver cells. In addition, the LD50 dose of carvone in rats was 1.707 mol/kg. Due to its interaction profile with target proteins and excellent pharmacokinetic properties, it has been concluded that carvone can be considered as an alternative agent in drug development studies against 2019-nCoV.

🔖

Bu Makaleye Atıf Yap

ISTİFLİ, E. S., TEPE, A. S., SARİKURKCU, C., TEPE, B. (2020). Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties. Turkish Journal of Biology, Cilt: 44 - Sayı: SI-1, 242–264. https://ajindex.com/articles/204389

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9 Thuy BTP, 2020, ACS OMEGA, V5, P8312, DOI 10.1021/acsomega.0c00772 Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421 Chan JFW, 2020,
  2. LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9 COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916 Corman VM, 2019,
  3. INTERNIST, V60, P1136, DOI 10.1007/s00108-019-00671-5 Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382 Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717 de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81 EVANS RM, 1988,
  4. SCIENCE, V240, P889, DOI 10.1126/science.3283939 Fehr AR, 2017, ANNU REV MED, V68, P387, DOI 10.1146/annurev-med-051215-031152 Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10 Greenspan PD, 2001, J MED CHEM, V44, P4524, DOI 10.1021/jm010206q Guan Y, 2003,
  5. SCIENCE, V302, P276, DOI 10.1126/science.1087139 Guex N, 2009,
  6. ELECTROPHORESIS, V30, pS162, DOI 10.1002/elps.200900140 Hardegger LA, 2011,
  7. CHEMMEDCHEM, V6, P2048, DOI 10.1002/cmdc.201100353 Hoffmann M, 2020,
  8. CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052 Huang CL, 2020,
  9. LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5 LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944 Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102 Li F, 2005,
  10. SCIENCE, V309, P1864, DOI 10.1126/science.1116480 Li WH, 2003,
  11. NATURE, V426, P450, DOI 10.1038/nature02145 Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1 Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10 Morris Garrett M., 2008, V443, P365, DOI 10.1007/978-1-59745-177-2_19 Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929 Nasab RR, 2017, RES PHARM SCI, V12, P425, DOI 10.4103/1735-5362.213988 Nguyen PH, 2020, BIOCHEM PHARMACOL, V174, DOI 10.1016/j.bcp.2020.113813 Pagliaro M., 2020,
  12. ACCELERATED PRODUCTI, DOI [10.20944/preprints202003.0386.v1, DOI 10.20944/PREPRINTS202003.0386.V1] Pedretti A, 2004, J COMPUT AID MOL DES, V18, P167, DOI 10.1023/B:JCAM.0000035186.90683.f2 Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104 Prakash D, 2007, INT J FOOD SCI NUTR, V58, P18, DOI 10.1080/09637480601093269 Rac A, 2020, DATA BRIEF, V28, DOI 10.1016/j.dib.2019.105038 Ramirez D, 2018,
  13. MOLECULES, V23, DOI 10.3390/molecules23051038 Remmert M, 2012, NAT METHODS, V9, P173, DOI [10.1038/NMETH.1818, 10.1038/nmeth.